PET Detection of CCR2 in Human Atherosclerosis

PHASE1RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

September 1, 2025

Study Completion Date

September 1, 2025

Conditions
Carotid Atherosclerosis
Interventions
DRUG

Group 1-64CU-DOTA-ECL1i (radioactive imaging medicine)

Patients in Group 1, normal volunteers and patients with carotid and femoral artery disease who will be having surgery, will have a 1 day imaging session lasting approximately 60 minutes with an injection of 64CU-DOTA-ECL1i to visualize the carotid and femoral arteries. Patients with carotid and femoral artery disease will have their plaque specimens collected for further sutdy

DRUG

Group 2 64CU-DOTA-ECL1i (radioactive imaging medicine)

Patients in Group 2, who are patients with carotid and femoral artery disease who will not be having surgery will have two imaging sessions 7-14 days apart

Trial Locations (1)

63110

RECRUITING

Washington University CCIR, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER